Differentiating Pluripotent Cells into Glucose-Responsive Insulin Producers

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods fail to produce reliable and scalable populations of glucose-responsive insulin-producing cells derived from human embryonic stem cells for treating insulin-dependent diabetes, lacking efficient differentiation protocols and enrichment techniques for pancreatic hormone-expressing cells.

Innovation Solution

The development of cell cultures and methods that enrich for human pancreatic islet hormone-expressing cells and endocrine precursor cells, using reagents like NCAM and CD133 to separate and differentiate cells, and employing growth factors such as activin A and exendin 4 to promote differentiation into mature and immature pancreatic islet hormone-expressing cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional differentiation protocols are used, then cell cultures can be maintained, but reliable and scalable production of glucose-responsive insulin-producing cells is not achieved

Engineering Contradiction:

Improveproduction of insulin-producing cellsVSAvoidreliability of glucose-responsive insulin production

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The differentiation process is divided into distinct stages with specific markers for identification and enrichment. Endocrine precursor cells expressing Neurogenin 3 are separated and enriched as an intermediate population before final differentiation into insulin-producing cells, enabling controlled progression through developmental stages to achieve reliable insulin production

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

Endocrine precursor cells expressing Neurogenin 3 are enriched and prepared in advance through selective cultivation and marker-based separation. This preliminary enrichment creates a standardized starting population that reliably differentiates into glucose-responsive insulin-producing cells when exposed to appropriate differentiation conditions

Inventive Principle:

Principle #10Preliminary action

2Productivity

If enrichment techniques are developed, then populations of pancreatic hormone-expressing cells can be increased, but process complexity increases

Engineering Contradiction:

Improvepercentage of hormone-expressing cellsVSAvoidcomplexity of enrichment protocol

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

Fluorescently labeled antibodies specific to Neurogenin 3 and other markers are used to tag endocrine precursor cells. Flow cytometry detects these fluorescent labels to identify and sort cells based on their marker expression, enabling precise enrichment without complex manual procedures

Inventive Principle:

Principle #32Color changes

Solution Approach 2:

Manual cell separation and identification methods are replaced with automated flow cytometry and magnetic-activated cell sorting (MACS) systems. These automated systems use antibody-labeling and magnetic or optical detection to enrich target cell populations, reducing procedural complexity while increasing enrichment efficiency

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Data Source

PatentUS7534608B2Methods of producing pancreatic hormones

Publication Date: 2009.05.19 VIACYTE INC

AI summary

Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.